Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection

Authors

DOI:

https://doi.org/10.33448/rsd-v10i3.13136

Keywords:

Coronavirus; Covid-19; SARS-CoV-2.

Abstract

Coronaviruses are viruses that cause respiratory infections that can affect animals and humans. The SARS-CoV-2 epidemic, which caused COVID-19, began in Wuhan (China) in December 2019, and spread to several countries, becoming a dangerous pandemic without specific treatment. This work aims to show cases treated with the main drugs for SARS-CoV-2, evaluating its efficacy and disadvantages. Publications with data from pharmacological treatments for the new SARS-CoV-2, scientific publications, world health organization (WHO) and governmental publications were used, among the date (2019-2020). Data were collected from the following scientific databases: LILACS, PUBMED, PERIODICOS, GOOGLE ACADEMICOS, SCIENCE DIRECT, BIRAME, Virtual Health Library - VHL, SCIELO, Cochrane Library, HighWire Press, Scopus and Elsevier; and the technological bases: WIPO and PTO. The use of these drugs may have led to improvement and cure of patients globally. They are believed to be effective against the disease. However, we need scientific proofs. In the results we observed the drugs used worldwide and the patents approved until (15/09/2020). There is no treatment for Covid19, medications that soften the flu-like symptoms of the disease were used. In emergency cases, the combination of the antibiotic azithromycin and hydroxychloroquine, used for malaria and other medicines, was used. This study evaluated most of the drugs that are in use for the treatment of SARS-CoV-2, in order to present a drug or more that is effective for the treatment of the disease, also showing whether in vitro and in vivo research was conducted in the search for a better treatment.

References

Atallah, A. N., Puga, M. E. D. S., Amaral, J. L. G. S. D., & Person, O. C. (2020). intervenção com cloroquina/hidroxicloroquina com ou sem azitromicina para covid-19 (sars-cov 2): sinopse baseada em evidências. Revista diagnóstico e tratamento. 25 (2): 01-07.

Bakheit, A. H., Al-Hadiya, B. M., & Abd-Elgalil, A. A. (2014). Azithromycin. Profiles of drug substances, excipients, and related methodology, 39 (1), 1–40.

Baron, S. A., Devaux, C., Colson, P., Raoult, D., & Rolain, J. M. (2020). Teicoplanin: an alternative drug for the treatment of COVID-19?. International journal of antimicrobial agents, 55(4), 105944.

Centro de operações de emergências em saúde pública - COE-covid (2020). Plano de Contingência Nacional para Infecção Humana pelo novo Coronavírus COVID-19. Ministério da Saúde.

Chan, J. F., Yuan, S., Kok, K. H., To, K. K., Chu, H., Yang, J. et al. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet (London, England), 395 (10223), 514–523.

Della-Torre, E., Campochiaro, C., Cavalli, G., De Luca, G., Napolitano, A., La Marca, S. et al. (2020). Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Annals of the rheumatic diseases, 79 (10), 1277–1285.

Elfiky A. A. (2020). Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life sciences, 253 (1), 117592.

Filho, A., J. B. A., Valente, M. Y. S., Nathan, A. C., Guido, G. C., Higa, C. N. (2020). Pneumonia por COVID-19: qual o papel da imagem no diagnóstico? J. Bras. Pneumol. 46 (2).

George, P. M., Wells, A. U., & Jenkins, R. G. (2020). Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. The Lancet. Respiratory medicine, 8(8), 807–815.

Hydroxychloroquine Sulfate Monograph for professional. (2020). The American Society of Health-System Pharmacists.

Imperador, C.H.L., Espreafico Junior, C.R., Nascimento, A.M.V. (2020). Cloroquina e hidroxicloroquina associado ao zinco e/ou azitromicina na COVID-19. Revista Ulakes. 1 (1), 67-73.

Lana, R. M., Coelho, F. C., Gomes, M. F. C., Cruz, O. G., Bastos, L. S., Villela, D. A. M., Codeço, C. T. 2020. Emergência do novo coronavírus (SARS-CoV-2) e o papel de uma vigilância nacional em saúde oportuna e efetiva. Cad. Saúde Pública. 36 (3), 1-5.

LTDA. (2013). Medley Farmacêutica. frmVisualizarBula.asp. Anvisa.

Madjd, Zahra. The Lancet Infectious Diseases Spotlight of Remdesivir in comparison with Ribavirin, Favipiravir, Oseltamivir and Umifenovir in Coronavirus Disease 2019 (COVID-19). The lancet. ID-D-20-01886.

Menezes, C.R., Sanches, C., Chequer, F.M.D. (2020). Efetividade e toxicidade da cloroquina e da hidroxicloroquina associada (ou não) à azitromicina para tratamento da COVID-19. O que sabemos até o momento? Journal of Health & Biological Sciences. 8 (1), 1-9.

Ministério da saúde. (2020). Secretária de Vigilância em saúde. Centro de operações de emergência de saúde pública. Boletim Epidemiológico Especial – COE Coronavírus.

Nobre, A. F. S., Sousa, R. C. M., Santos, M. C., Barbagelata, L. S., Júnior, E. C., Lima, D. F., et al. (2014). Primeira detecção de coronavírus humano associado à infecção respiratória aguda na Região Norte do Brasil. Rev Pan-Amaz Saúde, 5 (2), 37-41.

Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. Metodologia da pesquisa científica. UFSM.

Sandler, R. (2020). FDA aprova cloroquina e hidroxicloroquina para tratamento emergencial de coronavírus. Recuperado: https://forbes.com.br/colunas/2020/03/fda-aprova-cloroquina-e-hidroxicloroquina-para-tratamento-emergencial-de-coronavirus/>.

Sathyamoorthy, N., Chintamaneni, P. K., & Chinni, S. (2020). Plausible role of combination of Chlorpromazine hydrochloride and Teicoplanin against COVID-19. Medical hypotheses, 144, 110011.

Secretaria de Atenção Primária à Saúde (SAPS) - Ministério da Saúde. (2020). Protocolo de manejo clínico do coronavírus (COVID-19) na atenção primária à saúde.

Secretaria de Atenção Primária à Saúde (SAPS) - Ministério da Saúde. (2020b). Manejo de corpos no contexto do novo coronavírus COVID-19.

Secretaria do Estado de São Paulo. (2020a). Protocolo laboratorial para a coleta, acondicionamento e transporte de amostras biológicas para investigação de COVID-19.

Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020). COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet. Infectious diseases, 20 (4), 400–402.

Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y. et al. (2020). Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta pharmaceutica Sinica. B, 10 (5), 766–788.

Wu, T. C., Sacilotto, L., Darrieux, F. C. C., Pisani, C. F., Melo, S. L., Hachul, D. T. et al. (2020). Controle do Intervalo QT para Prevenção de Torsades de Pointes Durante uso de Hidroxicloroquina e/ou Azitromicina em Pacientes com COVID 19. Arquivos Brasileiros de Cardiologia. 114 (6), 1061-1066.

Xu, C., Zhu, L., Chan, T., Lu, X., Shen, W., Madigan, M. C. et al. (2016). Chloroquine and Hydroxychloroquine Are Novel Inhibitors of Human Organic Anion Transporting Polypeptide 1A2. Journal of pharmaceutical sciences, 105(2), 884–890.

Downloads

Published

12/03/2021

How to Cite

SILVA, K. M. R. da .; SILVA, P. B. da .; SILVA, H. J. N. da .; SILVA, P. T. da .; SILVA, B. L. .; FERREIRA, A. M. C. .; BEZERRA, W. A. dos S. .; SILVA, D. de A. e .; CAMPOS, M. R. de .; OLIVEIRA, D. M. T. e .; NASCIMENTO, A. L. L. do .; RIBEIRO, A. M. de C. .; SILVA, A. M. da .; SOUSA, E. A. .; OLIVEIRA, I. K. F. .; LOPES, M. M. F. .; ANDRADE, N. B. de .; PINHEIRO, I. M. .; FERREIRA, K. L. C. .; FURTADO, D. R. L. . Evaluation of the main pharmacies used for the sars-cov-2: a scientific and technological prospection . Research, Society and Development, [S. l.], v. 10, n. 3, p. e19310313136, 2021. DOI: 10.33448/rsd-v10i3.13136. Disponível em: https://www.rsdjournal.org/index.php/rsd/article/view/13136. Acesso em: 19 apr. 2024.

Issue

Vol. 10 No. 3

Section

Health Sciences

License

Copyright (c) 2021 Kelly Maria Rêgo da Silva; Pryscilla Bizerra da Silva; Higo José Neri da Silva; Pauliana Texeira da Silva; Bruna Layra Silva; Ana Maria Castro Ferreira; Wallyson André dos Santos Bezerra; Denilson de Araújo e Silva; Mariel Rodrigues de Campos; Deylane Menezes Teles e Oliveira; Antonia Luzia Lima do Nascimento; Alice Maria de Castro Ribeiro; Amanda Miranda da Silva; Emille Andrade Sousa; Iara Katrynne Fonsêca Oliveira; Michelle Maria Ferreira Lopes; Nathália Batista de Andrade; Iluska Martins Pinheiro; Kivia Ludmilla Carvalho Ferreira; Denis Romulo Leite Furtado

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.